tbuckley/cabot-search huggingface dataset:
Novel roles of DC-SIGNR in colon cancer cell adhesion, migration, invasion, and liver metastasis
Authors: Heya Na, Xiaoli Liu, Xiaomeng Li, Xinsheng Zhang, Yu Wang, Zhaohui Wang, Menglang Yuan, Yu Zhang, Shuangyi Ren, Yunfei Zuo
Journal: Journal of Hematology & Oncology (2017)

Tumor metastasis is an essential cause of the poor prognosis of colon cancer. DC-SIGNR is a C-type lectin that is frequently found on human liver sinusoidal endothelial cells. LSECtin, which is a homologue of DC-SIGNR, has been demonstrated to participate in colon cancer liver metastasis. Due to the similarities in the expression pattern and structure of the two proteins, we speculated that DC-SIGNR could also be involved in this process. Colon cancer cells were treated with the DC-SIGNR protein or control IgG, after which cell migration, invasion, and morphology were assayed. Xenograft mouse models were used to determine the role of DC-SIGNR in colon cancer liver metastasis in vivo. In addition, a human gene expression array was used to detect differential gene expression in colon cancer cells stimulated with the DC-SIGNR protein. The serum level of DC-SIGNR was examined in colon cancer patients by ELISA, and the significance of DC-SIGNR was determined. In our research, we investigated whether DC-SIGNR promotes colon cancer cell adhesion, migration, and invasion. Knocking down mouse DC-SIGNR decreased the liver metastatic potency of colon cancer cells and increased survival time. Expressing human DC-SIGNR enhanced colon cancer liver metastasis. Furthermore, DC-SIGNR conferred metastatic capability on cancer cells by upregulating various metallothionein isoforms. To validate the above results, we also found that the serum DC-SIGNR level was statistically higher in colon cancer patients with liver metastasis compared with those without metastasis. These results imply that DC-SIGNR may promote colon carcinoma hepatic metastasis and could serve as a promising therapeutic target for anticancer treatment.
Improved Post-Induction Chemotherapy Does Not Abrogate Prognostic Significance of Minimal Residual Disease (MRD) for Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (ALL). A Report From Children's Oncology Group (COG) Study AALL0232
Authors: Michael J. Borowitz, Brent L. Wood, Meenakshi Devidas, Mignon L Loh, Elizabeth A. Raetz, Wanda Salzer, James Nachman, Andrew J. Carroll, Nyla A. Heerema, Julie M. Gastier-Foster, Cheryl L Willman, Stephen B. Linda, Naomi Winick, Stephen Hunger, William L. Carroll, Eric C. Larsen
Journal: Blood (2011)
SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells
Authors: Tom L. Stephen, Kyle K. Payne, Ricardo A. Chaurio, Michael J. Allegrezza, Hengrui Zhu, Jairo Perez-Sanz, Alfredo Perales-Puchalt, Jenny M. Nguyen, Ana E. Vara-Ailor, Evgeniy B. Eruslanov, Mark E. Borowsky, Rugang Zhang, Terri M. Laufer, Jose R. Conejo-Garcia
Journal: Immunity (2017)
Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study
Authors: Michael Wang, Simon Rule, Peter Martin, Andre Goy, Rebecca Auer, Brad S. Kahl, Wojciech Jurczak, Ranjana Advani, Jorge E. Romaguera, Michael E. Williams, Jacqueline C. Barrientos, Ewa Chmielowska, John Radford, Stephan Stilgenbauer, Martin Dreyling, Wieslaw Wiktor Jedrzejczak, Peter W Johnson, Stephen E. Spurgeon, Liang Zhang, Linda Baher, Mei Cheng, Darrin M. Beaupre, Kristie A. Blum
Journal: Blood (2014)
Dasatinib 140 Mg Once Daily (QD) Has Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Imatinib-Resistant or -Intolerant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 2-Year Data from CA180- 035
Authors: Richard A. Larson, Oliver G. Ottmann, Neil P. Shah, Michael B. Lilly, Josy M. Reiffers, Aude Charbonnier, Gerhard Ehninger, M. Brigid Bradley-Garelik, Chao Zhu, Giovanni Martinelli
Journal: Blood (2008)
The Studies on the T-Cell Receptor Repertoire Diversity and Flow Cytometric Analysis in a Patient with MAS/HPS after Unrelated Peripheral Blood Stem Cell Transplantation.
Authors: Xin Du, Yangqiu Li, Suxia Geng, Jianyu Weng, Zesheng Lu, Suijin Wu, Chenxin Deng, Wei Ling, Haizhou Xing, Changchun Wan, Chenwei Luo, Liye Zhong, Miaorong She, Xiaoli Zhou, Qunhua Li, Wei Lin, Zilun Huang, Shaohua Chen
Journal: Blood (2007)
Baicalein Combined with Dexamethasone Can Induce the Marked PPARß-Mediated Suppression of Growth and Survival in Human Myeloma Cells.
Authors: Ken-ichiro Otsuyama, Jakia Amin, Emi Uchida, Saeid Abroun, Karim Shamsasenjan, Khademul Islam, Hideki Asaoku, Michio M. Kawano
Journal: Blood (2006)
Myeloma Cells Suppress Osteoblast Differentiation by Secreting a Soluble Wnt Inhibitor, sFRP-2.
Authors: Takashi Oshima, Masahiro Abe, Jin Asano, Tomoko Hara, Kenichi Kitazoe, Etsuko Sekimoto, Yoichi Tanaka, Hironobu Shibata, Toshihiro Hashimoto, Shuji Ozaki, Shinsuke Kido, Daisuke Inoue, Toshio Matsumoto
Journal: Blood (2004)
Achieving Complete Cytogenetic Response and BCR-ABL PCRIS <1% within 12 Moths Are Important Goals for Imatinib Therapy in Newly Diagnosed, TKI-Naive Chronic Myeloid Leukemia Accelated Phase Patients
Authors: Hawk Kim, Eun-Jung Jang, Sung-Eun Lee, Won Sik Lee, Sukjoong Oh, Dong-Wook Kim
Journal: Blood (2014)
In Vivo RNA Interference Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling
Authors: Fatima Al-Shahrour, Kimberly A. Hartwell, Lisa P Chu, Jaras Marcus, Rishi V Puram, Alexandre Puissant, Kevin Callahan, John M Ashton, Marie Ellen McConkey, Luke Poveromo, Glenn Cowley, Michael G Kharas, Myriam Labelle, Sebastian Shterental, Muhammad Al-Hajj, Christopher Shelton, Scott A. Armstrong, David E. Root, Richard Hynes, Siddhartha Mukherjee, Kimberly Stegmaier, Craig T. Jordan, Benjamin L. Ebert
Journal: Blood (2011)
Inflammasome Priming in Sterile Inflammatory Disease
Authors: Meghana N. Patel, Richard G. Carroll, Silvia Galván-Peña, Evanna L. Mills, Robin Olden, Martha Triantafilou, Amaya I. Wolf, Clare E. Bryant, Kathy Triantafilou, Seth L. Masters
Journal: Trends in Molecular Medicine (2017)
US Senate takes first step to repeal Affordable Care Act
Authors: Michael McCarthy
Journal: BMJ (2017)

The Republican controlled US Senate passed a budget measure in the early hours of 12 January that opens the way for repeal of the Affordable Care Act. The mostly party line vote came after a seven hour marathon “vote-a-rama,” during which Democrats offered a series of amendments to force Republicans to be on record as voting against many of the act’s most popular provisions.

Senator Mike Enzi, a Republican from Wyoming and chair of the Senate Budget Committee, said that passage of the measure was the “first step to repairing the nation’s broken healthcare system.” He added, “This resolution will set the stage for true legislative relief from Obamacare that Americans have long demanded, …
A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis
Authors: Càndid Villanueva, Isabel Graupera, Carles Aracil, Edilmar Alvarado, Josep Miñana, Ángela Puente, Virginia Hernandez‐Gea, Alba Ardevol, Oana Pavel, Alan Colomo, Mar Concepción, María Poca, Xavier Torras, Josep M. Reñe, Carlos Guarner
Journal: Hepatology (2017)

Monitoring the hemodynamic response of portal pressure (PP) to drug therapy accurately stratifies the risk of variceal rebleeding (VRB). We assessed whether guiding therapy with hepatic venous pressure gradient (HVPG) monitoring may improve survival by preventing VRB. Patients with cirrhosis with controlled variceal bleeding were randomized to an HVPG‐guided therapy group (N = 84) or to a control group (N = 86). In both groups, HVPG and acute β‐blocker response were evaluated at baseline and HVPG measurements were repeated at 2‐4 weeks to determine chronic response. In the HVPG‐guided group, acute responders were treated with nadolol and acute nonresponders with nadolol+nitrates. Chronic nonresponders received nadolol+prazosin and had a third HVPG study. Ligation sessions were repeated until response was achieved. The control group was treated with nadolol+nitrates+ligation. Between‐group baseline characteristics were similar. During long‐term follow‐up (median of 24 months), mortality was lower in the HVPG‐guided therapy group than in the control group (29% vs. 43%; hazard ratio [HR] = 0.59; 95% confidence interval [CI] = 0.35‐0.99). Rebleeding occurred in 19% versus 31% of patients, respectively (HR = 0.53; 95% CI = 0.29‐0.98), and further decompensation of cirrhosis occurred in 52% versus 72% (HR = 0.68; 95% CI = 0.46‐0.99). The survival probability was higher with HVPG‐guided therapy than in controls, both in acute (HR = 0.59; 95% CI = 0.32‐1.08) and chronic nonresponders (HR = 0.48; 95% CI = 0.23‐0.99). HVPG‐guided patients had a greater reduction of HVPG and a lower final value than controls ( P &lt; 0.05). Conclusion : HVPG monitoring, by stratifying risk and targeting therapy, improves the survival achieved with currently recommended treatment to prevent VRB using β‐blockers and ligation. HVPG‐guided therapy achieved a greater reduction in PP, which may have contributed to reduce the risk of rebleeding and of further decompensation of cirrhosis, thus contributing to a better survival. (H epatology 2017;65:1693‐1707).
α-basic-crystallin expression in basal-like breast cancer and its association with brain metastasis
Authors: H. F. Kennecke, D. Voduc, S. Leung, V. L. Cryns, C. M. Perou, T. O. Nielsen, M. Cheang
Journal: Journal of Clinical Oncology (2009)

1025 Background: Basal-like breast cancers are high grade tumors with poor prognosis, having propensity for brain and lung metastasis (Perou et al. Nature 406:747–52, 2000, Cheang et al. Clin Cancer Res 14:1368–76, 2008, Luck et al. Clin Oncol (R Coll Radiol) 20:40–5, 2008). α-basic-crystallin (αBC), a small heat shock protein with anti-apoptotic and oncogenic activity, is expressed in about half of basal-like breast cancers but only 6% of other types (Moyano et al. J Clin Invest 116:261–70, 2006). Here we investigate the association of αBC with sites of distant metastasis in a large cohort of breast cancer patients. Methods: Our cohort consists of 4046 early invasive breast cancers referred to the British Columbia Cancer Agency from 1986 to 1992. Archival paraffin tissue blocks were used to construct tissue microarrays. Breast cancer subtypes were defined using a surrogate of six immunohistochemical markers: ER, PR, HER2, Ki-67, epidermal growth factor receptor and cytokeratin 5/6. αBC immunostaining was scored by pre-established, published criteria. All documented sites of distant metastasis were abstracted by chart review according to predefined categories. The null hypothesis was tested using chi-square and Fisher's Exact tests; all tests were two-sided. Results: Among 3,248 cases with interpretable αBC data, 11% were αBC +. Among patients who developed distant metastatic disease, the 10-yr BCSS survival in αBC+ and - tumors was 12% and 29%. Sites of metastatic disease included: brain (15%), lung (35%), liver (35%) and bone (65%). Brain metastasis was significantly more common among αBC positive tumors (Fisher's Exact test p&lt;10e-8). Basal-like tumors with brain metastasis commonly co-expressed αBC (Chi-square p=0.006). Conclusion: αBC is significantly associated with brain metastasis, particularly among basal breast cancers. These findings suggested that αBC may be involved in tumor cell metastasis and may allow early identification of a subset of patients at particularly high risk of brain metastasis. [Table: see text] No significant financial relationships to disclose.
Bone Marrow-Derived Cell Mobilization with G-CSF and GM-CSF in Patients with Acute Myocardial Infarction: A Pilot Study on Feasibility, Safety and Efficacy.
Authors: Corrado Tarella, Paolo Scacciatella, Giacomo Tamponi, Giorgio Millesimo, Massimo Baccega, Tullio Usmiani, Marco Sicuro, Maurizio D’Amico, Mauro Giorgi, Luca Checco, Mario Campana, Pierluigi Sbarra, Irene Ricca, Paola Omedè, Fiorella Sanavio, Mario Boccadoro, Michele Casaccia, Sebastiano Marra
Journal: Blood (2004)
Fluorescent PCR Based Gene Dose Assessment for Detection of Deletion Mutations in the FIX Gene Among Carriers of Hemophilia B.
Authors: Eunice Sindhuvi Edison, G. Sankari Devi, G. Jayandharan, Shaji R Velayudhan, Auro Viswabandya, Vikram Mathews, Mammen Chandy, Alok Srivastava
Journal: Blood (2009)
Differences in Natural Killer(NK) Reconstitution Between Unmanipulated Haploidentical and HLA Identical Stem Cell Transplantation and Relationship with Citomegalovirus and Graft Versus Host Disease (GVHD). Experience in One Centre in 22 Patients.
Authors: Ana María Pérez-Corral, Ana Carolina Franco, Diana Champ, Jorge Gayoso, Cristina Pascual, Mariana Bastos-Oreiro, Mi Kwon, David Serrano, Pascual Balsalobre, Ismael Buno, Carolina Martínez-Laperche, Elizabeth Sarmiento, Javier Anguita, Jose Luis Diez-Martin
Journal: Blood (2014)
Emerging and Reemerging Infectious Diseases
Authors: Catharine I. Paules, Anthony S. Fauci
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Use of Dendritic Cells Versus Peripheral Blood Lymphocytes To Segregate Alloreactive and Regulatory T Cells during Allogeneic Transplantation.
Authors: Tami Katz, Irit Avivi, Dina Stroopinski, Anna Oliven, Tsila Zuckerman, Sandra Karitzky, Guy Moeneclaey, Baldev Vasir, Jacalyn Rosenblatt, Corrie Lenahan, Jacob M. Rowe, David Avigan
Journal: Blood (2005)
Clinical and Laboratory Studies of 23 Patients with Acute Myeloid Leukemia Harboring t(7; 11) (p15; p15) Translocation
Authors: Shuning Wei, Siping Wang, Shaowei Qiu, Junyuan QI, Yingchang Mi, Dong Lin, Chunlin Zhou, Bingcheng Liu, Ying Wang, Min Wang, Jianxiang Wang
Journal: Blood (2015)
LONG-TERM RESULTS OF LIVER TRANSPLANTATION WITH A NATIONAL PROTOCOL FOR CONTROLLED CARDIAC DEATH DONORS
Authors: Jeroen Dubbeld, Harm Hoekstra, Waqar R. R. Farid, Jan Ringers, Robert J. Porte, Herold J. Metselaar, Andrzej G. Baranski, Geert Kazemier, Minneke J. Coenraad, Aad P. van den Berg, Bart Van Hoek
Journal: Hepatology (2009)
Sequelae of Donor-derived Mollicutes Transmission in Lung Recipients
Authors: Ramiro Fernandez, Monica Chi, Michael G. Ison, Ken B. Waites, Donna M. Crabb, Amy E. Ratliff, Hector Cajigas, Malcolm M. DeCamp, David Odell, G. R. Scott Budinger, Ankit Bharat
Journal: American Journal of Respiratory and Critical Care Medicine (2017)
Acute Lymphoblastic Leukemia in Japanese Adolescents; Biology and Toxicity Profile
Authors: So-ichi Suenobu, Atsushi Sato, Yoshihiro Takahashi, Ikuya Usami, Shin-ichiro Nishimura, Daiichiro Hasegawa, Yoshiko Hashii, Nobuhiro Suzuki, Akiko Saito, Hirohide Kawasaki, Keiko Yagi, Keizo Horibe, Junichi Hara, Hiroki Hori, Megumi Oda
Journal: Blood (2012)
Proteomic Characterization of Vascular Endothelial Cell-Conditioned Medium Chemo-Attractive to Umbilical Cord Blood Monocytes: Implications for Angiogenesis in Response to Hypoxia.
Authors: Graham C. Chapman, Mathew Lawrence Lesniewski, Chao Yuan, Richard Patrick Weitzel, Nicholas J Greco, Laura Fanning, Gordon Preston, Aaron R. Victor, Philip Paul, Mark Chance, Mary J. Laughlin
Journal: Blood (2009)
Comparison Between Pegfilgrastim and Filgrastim-Based Autologous Hematopoietic Stem Cell Mobilization in the Setting of Patient Adapted (“Just in Time”) Plerixafor: Efficacy and Cost Analysis
Authors: Luciano J Costa, Kathy Hogan, Cindy Kramer, Coleen Butcher, Amanda Littleton, Katie B Shoptaw, Yubin Kang, Robert K Stuart
Journal: Blood (2011)
Newspaper response to the back pain myth busting advice: bruising but helpful
Authors: Christopher J McCarthy, Gillian Yeowell
Journal: British Journal of Sports Medicine (2017)

Following on from recent newspaper articles,1 BJSM podcasts2 and the Chartered Society of Physiotherapy's recent Back Pain Myth buster campaign,3 a short article was published in the Daily Mail Online 4 in August of this year. The article summarised the messages of the back pain myth buster campaign and advocated basic evidence-based approaches to exercise and management. The article was accessed over 29 000 times with 125 reader comments being posted in the following 2 weeks.

Having reviewed the comments, it became apparent that there were a number of themes within the data and thus a colleague and I undertook a thematic analysis of the comments …
A randomized, phase II study of repeated rhenium-188-HEDP (rhenium) combined with docetaxel versus docetaxel alone in castration resistant prostate cancer (CRPC) metastatic to bone: The Taxium II trial.
Authors: Joyce M. van Dodewaard-de Jong, Haiko Bloemendal, John M. H. de Klerk, Daniela E Oprea-Lager, Otto S. Hoekstra, H Pieter van den Berg, Maartje Los, Aart Beeker, Joe M. O'Sullivan, Henk M.W. Verheul, Alfonsus Johannes Maria van den Eertwegh
Journal: Journal of Clinical Oncology (2016)

5081 Background: Docetaxel is first line chemotherapy in CRPC. Re-188 is a beta-emitting radiopharmaceutical that targets bone metastases. We investigated whether treatment with docetaxel plus Re-188 improved efficacy of first line chemotherapy. Methods: Patients with progressive CRPC and osteoblastic bone metastases were randomized for first line docetaxel 75 mg/m2 3-weekly plus prednisone with or without 2 injections of Re-188 after the 3rd (40 MBq/kg) and after the 6th (20 MBq/kg) cycle of docetaxel. Primary endpoint was progression free survival (PFS), a composite endpoint of either PSA, radiographic or clinical progression. 88 men were included to detect a targeted improvement of PFS at 6 months from 60% in the control group to 75% in the experimental group (power 77%; one-sided significance level 0.05; considered drop-out rate 10%). Patients were stratified by extent of bone metastases and hospital. Results: 42 patients received standard treatment and 46 patients combination therapy. Median number of cycles of docetaxel was 9 in the control group and 8 in the experimental group. Median follow up was 18.4 months. Two patients from the experimental group did not start treatment after randomization but intention to treat analysis was performed. No differences in PFS, survival and PSA became apparent between the two groups. In general pain responses were comparable, but musculoskeletal pain was reported less frequently in the combination group compared to control (88% versus 68%; p 0.024). Neutropenia grade 3/4 was more often seen in the combination group (16%) than in the control group (5%), but no differences in neutropenic fever (16% vs 14% respectively). Conclusions: Combined treatment with Re-188 and docetaxel is safe and feasible but does not improve PFS in patients with CRPC. However incidence of musculoskeletal pain was lower with combination therapy. Docetaxel (n = 42) Docetaxel and Re-188 (n = 46) P-value PFS in months 0.321 median 8.6 10.1 95% CI (7.9 – 9.3) (8.1 – 12.1) Overall survival in months 0.718 median 21.0 23.7 95% CI (18,7 – 23,3) (15,8 – 31,6) PSA response (≥ 50% decline from baseline) % 61.9 56.5 0.608
Urokinase-Type Plasminogen Activator Receptor (uPAR, CD87) Regulates Integrin Redistribution in Endothelial Cells Via Interaction with Low Density Lipoprotein Receptor- (LDLR-) Like Proteins
Authors: Gerald Prager, Rene Novotny, Matthias Unseld, Marina Poettler, Waclawa Kalinowska, Johannes Breuss, Christoph Zielinski
Journal: Blood (2011)
BRAF V600E Mutation Is not Always Present as Expected! A Case Report of Lung and Thyroid Carcinomas
Authors: Nicolas Piton, Mathieu Salaün, Florian Guisier, Florent Marguet, Emmanuel K. Touré, Pierre Gémival, Luc Thiberville, Jean-Christophe Sabourin
Journal: Journal of Thoracic Oncology (2017)
Outcomes of Patients with Myelodysplastic Syndromes/Myeloproliferative Neoplasms with Emphasis On MDS/MPN-Unclassified
Authors: Charikleia Kelaidi, Varnavas Constantinou, George Papaioannou, Niki Stavroyianni, Chrysanthi Vadikoliou, Damianos Sotiropoulos, Riant Saloum, Theodora Papadaki, Anastasia Athanasiadou, Achilles Anagnostopoulos
Journal: Blood (2011)
Single Centre Evaluation of Endocrine Complications in Children Treated with Auto- and Allo-Haematopoietic Stem Cell Transplantation (HSCT).
Authors: Dorota M. Wojcik, Ewa Niedzielska, Ewa Barg, Krzysztof Kalwak, Ewa Gorczynska, Adrian Doroszko, Alicja Chybicka
Journal: Blood (2006)
P0129 : Portal hypertension and collateral circulation can influence on the estimation of liver stiffness measurement by transient elastography
Authors: S.K. Baik, Y.L. Lim, Y.Z. Cho, M.Y. Kim, Y.O. Jang, K.T. Suk, G.J. Cheon, Y.D. Kim, D.H. Choi
Journal: Journal of Hepatology (2015)
Rhazes—His Life and Contributions to the Field of Dermatology
Authors: Mohammad Hashem Hashempur, Mohammad Mahdi Hashempour, Seyed Hamdollah Mosavat, Mojtaba Heydari
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Primary Mediastinal Large B Cell Lymphoma: Elucidating Optimal Therapy and Prognostic Factors; an Analysis in 141 Consecutive Patients Treated at Memorial Sloan Kettering from 1980–1999.
Authors: Paul A. Hamlin, Carol S. Portlock, David J. Straus, Ariela Noy, Steven M. Horwitz, Owen O’Connor, Joachim Yahalom, Andrew D. Zelenetz, Craig H. Moskowitz
Journal: Blood (2004)
Ендоскопія з високою роздільною здатністю та NBI в діагностиці уражень слизової оболонки верхніх відділів травного тракту
Authors: Yu.M. Stepanov, O.O. Krylovа
Journal: GASTROENTEROLOGY (2014)

У статті наведено можливості сучасної ендоскопії в отриманні якісних зображень слизової оболонки верхніх відділів травного тракту з застосуванням технологій високої роздільної здатності, збільшення та вузького спектра, що значно покращує візуалізацію капілярів та інших структур поверхні слизової оболонки. Використання ендоскопії зі збільшенням, хромоскопії та вузькоспектральної ендоскопії значно покращує якість огляду, скорочує час дослідження та число виконуваних біопсій.